These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 17425746)

  • 21. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
    Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
    Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The toxicity of busulphan and cyclophosphamide as the preparative regimen for allogeneic peripheral blood stem cell transplantation].
    Zhu K; Xu Y; Wu D; Xu X; Huang L
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):403-5. PubMed ID: 11877010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
    Iravani M; Evazi MR; Mousavi SA; Shamshiri AR; Tavakoli M; Ashouri A; Samiee S; Chahardovali B; Alimoghaddam K; Ghaffari SH; Ghavamzadeh A
    Bone Marrow Transplant; 2007 Jul; 40(2):105-10. PubMed ID: 17468775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan.
    Kusama M; Kubota T; Matsukura Y; Matsuno K; Ogawa S; Kanda Y; Iga T
    Clin Chim Acta; 2006 Jun; 368(1-2):93-8. PubMed ID: 16448639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.
    Grigg AP; Gibson J; Bardy PG; Reynolds J; Shuttleworth P; Koelmeyer RL; Szer J; Roberts AW; To LB; Kennedy G; Bradstock KF
    Biol Blood Marrow Transplant; 2007 May; 13(5):560-7. PubMed ID: 17448915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Homozygous status for HLA-E*0103 confers protection from acute graft-versus-host disease and transplant-related mortality in HLA-matched sibling hematopoietic stem cell transplantation.
    Tamouza R; Busson M; Rocha V; Fortier C; Haddad Y; Brun M; Boukouaci W; Bleux H; Socié G; Krishnamoorthy R; Toubert A; Gluckman E; Charron D
    Transplantation; 2006 Dec; 82(11):1436-40. PubMed ID: 17164714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia].
    Tong XZ; Xu DR; Zou WY; Li J; Luo SK; Peng AH; Zhang GC; Zheng D
    Ai Zheng; 2007 Aug; 26(8):914-8. PubMed ID: 17697559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IL-6 and IL-10 promoter gene polymorphisms of patients and donors of allogeneic sibling hematopoietic stem cell transplants associate with the risk of acute graft-versus-host disease.
    Karabon L; Wysoczanska B; Bogunia-Kubik K; Suchnicki K; Lange A
    Hum Immunol; 2005 Jun; 66(6):700-10. PubMed ID: 15993715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate.
    Murphy N; Diviney M; Szer J; Bardy P; Grigg A; Hoyt R; King B; Macgregor L; Holdsworth R; McCluskey J; Tait BD
    Bone Marrow Transplant; 2006 Apr; 37(8):773-9. PubMed ID: 16518429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IL2 and TNFA gene polymorphisms and the risk of graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.
    Viel DO; Tsuneto LT; Sossai CR; Lieber SR; Marques SB; Vigorito AC; Aranha FJ; de Brito Eid KA; Oliveira GB; Miranda EC; de Souza CA; Visentainer JE
    Scand J Immunol; 2007 Dec; 66(6):703-10. PubMed ID: 18021367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.
    Ansari M; Lauzon-Joset JF; Vachon MF; Duval M; Théoret Y; Champagne MA; Krajinovic M
    Bone Marrow Transplant; 2010 Feb; 45(2):261-7. PubMed ID: 19584821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gastrointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versus-host disease.
    Goldberg J; Jacobsohn DA; Zahurak ML; Vogelsang GB
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):101-7. PubMed ID: 15682070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
    Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
    Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy.
    Copelan EA; Penza SL; Theil KS; Elder PJ; Bechtel TP; Tighe MB; Ezzone SA; Scholl MD; Belt PS; Young DC; Avalos BR
    Bone Marrow Transplant; 2000 Nov; 26(10):1037-43. PubMed ID: 11108300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TNF polymorphisms are associated with toxic but not with aGVHD complications in the recipients of allogeneic sibling haematopoietic stem cell transplantation.
    Bogunia-Kubik K; Polak M; Lange A
    Bone Marrow Transplant; 2003 Sep; 32(6):617-22. PubMed ID: 12953135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
    Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
    Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Donor CD31 genotype and its association with acute graft-versus-host disease in HLA identical sibling stem cell transplantation.
    Goodman RS; Ewing J; Evans PC; Craig J; Poulton K; Dyer PA; Marcus RE; Taylor CJ
    Bone Marrow Transplant; 2005 Jul; 36(2):151-6. PubMed ID: 15908974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
    Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
    Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.